Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors (CAMELLIA-TIMI 61)
Status:
Completed
Phase of Trial:
Phase III/IV
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Lorcaserin (Primary)
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
- Acronyms CAMELLIA-TIMI; CAMELLIA-TIMI 61
- Sponsors Eisai Inc
- 22 Dec 2023 Results of Pooled Analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61, assessing interaction between body mass index (BMI) and NT-proBNP with respect to heart failure (HF) risk , published in the European Journal of Heart Failure
- 15 Nov 2021 Results assessing prognostic value of echocardiographic markers of diastolic dysfunction for heart failure in overweight and obese patients, presented at the American Heart Association Scientific Sessions 2021.
- 10 Sep 2020 Results published in the New England Journal of Medicine